Prenetics Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million Transaction

Bolsters Prenetics’ pro-forma cash reserves to approximately US$86 million, and pro-forma cash and short-term assets to approximately US$117 millionPrenetics simplifies investment thesis as company focuses on high-growth consumer health brands IM8, CircleDNA, and EuropaPrenetics raised its FY2025 outlook to be US$80 – US$100 million from $73 – US$85 million, driven by the growth of IM8 CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics”), a leading consumer ...